Bulk Pharmaceutical API Sources for bupivacaine hydrochloride

Bulk Pharmaceutical API Sources for bupivacaine hydrochloride

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-003-666-503
TimTec		ST013772
BioChemPartner		BCP9000461
AKos Consulting & Solutions		AKOS015889322
TCI (Tokyo Chemical Industry)		B3925
Finetech Industry Limited		FT-0607564
Finetech Industry Limited		FT-0623287

Bupivacaine Hydrochloride API Sourcing Landscape

Last updated: February 19, 2026

Summary:

Bupivacaine hydrochloride API is a widely utilized local anesthetic. Sourcing focuses on manufacturers with established regulatory compliance, robust quality control, and competitive pricing. Key considerations include Good Manufacturing Practice (GMP) certification, impurity profiles, and supply chain reliability. The market is characterized by both established Western pharmaceutical ingredient suppliers and a growing number of manufacturers in Asia, particularly India and China, offering cost advantages.

What are the primary sources for bulk bupivacaine hydrochloride API?

The primary sources for bulk bupivacaine hydrochloride API are specialized chemical manufacturers and pharmaceutical ingredient suppliers. These entities operate under strict regulatory oversight to ensure product quality and safety for pharmaceutical use.

• Major API Manufacturers: Companies with extensive experience in synthesizing complex organic molecules and established pharmaceutical dossiers are key suppliers. These often include both multinational corporations and regional leaders.
• Contract Development and Manufacturing Organizations (CDMOs): CDMOs that specialize in API production for the pharmaceutical industry are significant contributors to the bupivacaine hydrochloride supply chain. They offer manufacturing capabilities and regulatory expertise.
• Specialty Chemical Companies: Certain chemical companies focus on producing high-purity active pharmaceutical ingredients, meeting the stringent requirements of the pharmaceutical sector.

Which regions are dominant in bupivacaine hydrochloride API production?

Production of bupivacaine hydrochloride API is geographically distributed, with several regions holding significant market share.

• India: A leading global hub for pharmaceutical API manufacturing, India benefits from a large chemical industry, skilled workforce, and cost-effective production. Numerous Indian companies hold US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals for their facilities and products.
• China: China has emerged as a major producer of various APIs, including bupivacaine hydrochloride. Similar to India, its production is driven by scale, cost efficiency, and a growing emphasis on regulatory compliance.
• Europe: Several European countries have established pharmaceutical ingredient manufacturers with a long history of producing high-quality APIs. These suppliers often cater to markets demanding stringent regulatory adherence and are known for their advanced manufacturing processes.
• North America: While production exists, North America often focuses on specialized or higher-value APIs. Some domestic manufacturers contribute to the bupivacaine hydrochloride supply, particularly for the domestic market.

What are the key regulatory requirements for bupivacaine hydrochloride API suppliers?

Suppliers of bupivacaine hydrochloride API must adhere to rigorous regulatory standards to ensure product quality, safety, and efficacy.

• Good Manufacturing Practice (GMP): Compliance with current GMP guidelines (cGMP) as defined by regulatory bodies such as the FDA (21 CFR Parts 210 & 211), EMA, and WHO is mandatory. This covers all aspects of production, including facility design, equipment, personnel, raw material control, manufacturing processes, quality control, and documentation.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory authorities (e.g., FDA's Type II DMF). These confidential documents contain detailed information about the API's chemistry, manufacturing, and controls (CMC), allowing drug product manufacturers to reference the DMF in their drug applications without disclosing proprietary API information.
• Certificate of Analysis (CoA): Each batch of bupivacaine hydrochloride API must be accompanied by a CoA. This document details the results of quality control testing performed on the batch, including identity, purity, potency, and impurity levels, against pre-defined specifications.
• Impurity Profiling and Control: Suppliers must meticulously characterize and control impurities, including related substances, residual solvents, and elemental impurities, according to ICH guidelines (e.g., ICH Q3A/B/C/D). Limits for known and unknown impurities must be established and met.
• Stability Studies: Manufacturers must conduct comprehensive stability studies to determine the shelf-life of the API under specified storage conditions. This data is crucial for establishing retest dates or expiry dates.
• Site Audits and Inspections: API manufacturing sites are subject to regular audits by customers and inspections by regulatory agencies to verify GMP compliance.

What are the typical specifications for bupivacaine hydrochloride API?

Specifications for bupivacaine hydrochloride API are defined by pharmacopoeias and the individual manufacturer's quality standards, which are referenced in their DMFs.

• Assay (Potency): Typically not less than 98.0% and not more than 102.0% of bupivacaine hydrochloride, calculated on the dried or anhydrous basis. (e.g., USP, EP).
• Identification: Tests to confirm the identity of the substance, often including infrared (IR) spectroscopy, high-performance liquid chromatography (HPLC) retention time, and chemical tests.
• Appearance: White or almost white crystalline powder.
• Solubility: Freely soluble in water and ethanol; sparingly soluble in ether.
• pH: A solution of the API in water typically falls within a specified pH range (e.g., 4.0-6.0 for a 1% solution).
• Loss on Drying: Limits the amount of volatile matter (e.g., not more than 1.0%).
• Residue on Ignition/Sulfated Ash: Measures inorganic impurities (e.g., not more than 0.1%).
• Heavy Metals: Limits for heavy metal contamination (e.g., not more than 10 ppm).
• Related Substances/Impurities: Limits for specified and unspecified impurities determined by HPLC. Individual unspecified impurities are typically limited to a low percentage (e.g., not more than 0.10%), and the total impurities are also controlled (e.g., not more than 0.5%). Specific known impurities will have their own defined limits.
• Residual Solvents: Limits for residual solvents used in the manufacturing process, as per ICH Q3C guidelines (e.g., Class 1, 2, and 3 solvents).

How does the impurity profile impact API sourcing decisions?

The impurity profile is a critical factor in selecting bupivacaine hydrochloride API suppliers. Variations in impurities can affect the safety, efficacy, and stability of the final drug product.

• Safety Concerns: Certain impurities, even at low levels, can be toxic or genotoxic. Suppliers must demonstrate robust control over known toxic impurities and have sensitive analytical methods to detect and quantify them.
• Process Consistency: A consistent impurity profile across different batches indicates a well-controlled manufacturing process. Significant batch-to-batch variation in impurities can signal process instability or raw material variability.
• Regulatory Scrutiny: Regulatory agencies scrutinize impurity profiles closely. Suppliers with well-characterized and controlled impurity profiles are favored, as they reduce the regulatory burden on the drug product manufacturer.
• Analytical Method Validation: The validation status and sensitivity of a supplier's analytical methods for impurity testing are important. Robust methods ensure accurate reporting and control of impurities.
• Impact on Formulation: Certain impurities can affect the physical or chemical properties of the API, potentially influencing formulation development and the stability of the final dosage form.
• Sourcing Risk: A supplier with a history of uncontrolled or poorly characterized impurities poses a significant risk to the supply chain and product quality.

What are the pricing dynamics and cost drivers for bupivacaine hydrochloride API?

Pricing for bupivacaine hydrochloride API is influenced by several factors, leading to variations in cost.

• Raw Material Costs: The cost and availability of key starting materials and reagents used in the synthesis of bupivacaine hydrochloride are significant cost drivers. Fluctuations in commodity chemical prices can impact API cost.
• Manufacturing Scale and Efficiency: Larger-scale production generally leads to lower per-unit costs due to economies of scale. Manufacturers with highly optimized and efficient synthetic routes and manufacturing processes can offer more competitive pricing.
• Regulatory Compliance Costs: Meeting and maintaining GMP standards, conducting extensive quality control testing, stability studies, and regulatory filings (e.g., DMFs) involve substantial costs. Suppliers with established regulatory track records often have higher overheads but offer greater assurance.
• Geographic Location: Manufacturing costs vary significantly by region. Countries with lower labor costs, less stringent environmental regulations (though this is changing), and supportive government policies for the pharmaceutical industry often offer lower API prices.
• Purity and Specification Requirements: APIs meeting tighter specifications, particularly with very low impurity limits, may command higher prices due to the additional purification steps and rigorous testing required.
• Supply and Demand: Market dynamics, including global demand for bupivacaine hydrochloride and the number of qualified suppliers, influence pricing. Shortages or oversupply can lead to price volatility.
• Supplier Relationship and Volume: Long-term supply agreements and large-volume purchases can often result in more favorable pricing from suppliers.

What are the key considerations for ensuring supply chain reliability for bupivacaine hydrochloride API?

Ensuring a reliable supply of bupivacaine hydrochloride API is paramount for uninterrupted drug manufacturing.

• Supplier Qualification and Audits: Conducting thorough due diligence on potential suppliers, including on-site audits of their manufacturing facilities and quality systems, is essential. This verifies their GMP compliance, capacity, and ability to meet specifications consistently.
• Dual Sourcing Strategy: To mitigate risks associated with single-supplier dependency, drug manufacturers often pursue a dual-sourcing strategy. This involves qualifying at least two suppliers for critical APIs like bupivacaine hydrochloride, preferably from different geographic regions.
• Supply Agreements: Robust supply agreements should clearly define product specifications, quality standards, lead times, delivery schedules, pricing, and change control procedures. They should also include provisions for business continuity and disaster recovery.
• Inventory Management: Maintaining appropriate safety stock levels for the API can buffer against unexpected supply disruptions, such as manufacturing issues, transportation delays, or geopolitical events.
• Regulatory Status of Suppliers: Verifying that suppliers have the necessary regulatory approvals and that their DMFs are up-to-date and in good standing with relevant health authorities is critical.
• Geographic Diversification: Sourcing from suppliers in different geographic regions can reduce vulnerability to localized disruptions like natural disasters, political instability, or trade restrictions.
• Communication and Transparency: Open communication channels with suppliers are vital for early detection of potential issues, such as production delays or changes in raw material availability.

Key Takeaways

The global bupivacaine hydrochloride API market is characterized by a diverse supplier base, with significant production concentrated in India and China, offering competitive pricing and scale. European and North American manufacturers often focus on higher-value, specialized production with established regulatory track records. Stringent adherence to GMP, robust impurity control, and detailed DMF filings are non-negotiable regulatory requirements for all suppliers. Critical sourcing decisions hinge on a supplier's demonstrated quality control, regulatory compliance, capacity, and supply chain reliability. Drug manufacturers must implement rigorous supplier qualification programs, consider dual-sourcing strategies, and maintain strong supply agreements to ensure a consistent and high-quality API supply.

Frequently Asked Questions

1. What is the typical lead time from order placement to delivery for bupivacaine hydrochloride API from major suppliers? Lead times can vary significantly, typically ranging from 8 to 20 weeks for custom manufacturing campaigns or standard stock replenishment, depending on the supplier's production schedule, order volume, and current inventory levels.

2. Are there specific bupivacaine hydrochloride API manufacturers that are consistently preferred by major pharmaceutical companies? Preferences are driven by rigorous qualification processes and long-term performance. Companies like Fresenius Kabi, Siegfried, and established Indian players such as Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, and Cipla are recognized for their API manufacturing capabilities and regulatory compliance.

3. How does the presence of stereoisomers affect bupivacaine hydrochloride API sourcing and specifications? Bupivacaine is a chiral molecule, existing as a racemic mixture of R-(-)- and S-(+)-enantiomers. Standard bupivacaine hydrochloride API is supplied as the racemate. If an enantiomerically pure form (e.g., levobupivacaine) is required, it necessitates sourcing from specialized manufacturers with chiral synthesis or resolution capabilities, and distinct specifications will apply.

4. What are the implications of a DMF being placed on "inactivated" status by the FDA for an API supplier? An inactivated DMF means the FDA has not reviewed the filing for some time or it is otherwise not considered current. This can lead to delays or complications when a drug product manufacturer references that DMF in their submission, potentially requiring the supplier to re-activate or update the filing, or the drug product manufacturer to seek alternative API sources.

5. Can a bupivacaine hydrochloride API supplier be disqualified for issues found during customer audits? Yes, customer audits are part of supplier qualification and ongoing monitoring. Disqualifying findings related to significant deviations from GMP, quality system failures, or inability to meet critical specifications can lead to immediate disqualification and termination of supply contracts.

Citations

[1] United States Food and Drug Administration. (n.d.). Code of Federal Regulations Title 21, Part 210: Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General. U.S. Government Publishing Office. [2] United States Food and Drug Administration. (n.d.). Code of Federal Regulations Title 21, Part 211: Current Good Manufacturing Practice for Finished Pharmaceuticals. U.S. Government Publishing Office. [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Quality Guidelines. ICH. [4] United States Pharmacopeial Convention. (n.d.). USP Drug Standards | Bupivacaine Hydrochloride. USP. [5] European Directorate for the Quality of Medicines & HealthCare. (n.d.). EDQM. European Directorate for the Quality of Medicines & HealthCare.